Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

http://www.wikidata.org/entity/Q35134599

about

A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design "One-size-fits-all"? Optimizing treatment duration for bacterial infections Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.Therapeutic drug monitoring of antimicrobials.SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.Pharmacodynamic modelling of in vitro activity of tetracycline against a representative, naturally occurring population of porcine Escherichia coli.Continuous beta-lactam infusion in critically ill patients: the clinical evidence Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Novel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms.Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model.Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.

P2860

Q28476705-78CCC2DD-6D19-48B9-A778-4BEFF8D3DD0C Q28478851-78CACF3C-FDA7-4F82-818D-93CCB711E85B Q28550711-EFB1F712-1352-4D8A-B12C-250E78FF61BA Q28601378-BEDF2B18-D830-44F3-9F08-231622F26601 Q33555316-9ED4874E-F5B1-4F23-938D-FAF68CC7AFCA Q33826267-20559F6E-3BE3-4604-A7C5-25F41D36CA3A Q33836597-449E5A13-36BB-47D9-9CBB-F7167366C35A Q33876563-9D8DFD06-1CDB-4644-A76B-AE1C01EFAA59 Q33979438-F28A3F9E-1E62-4522-AC92-526CFBE516B0 Q33980421-DCEDFE24-BD7F-486F-8E6C-13085244C98B Q34737629-07DCFB85-58C3-4BDC-A0AB-AF3A4DAB89D5 Q35023303-A2E291A1-7E47-4B6B-A1CF-BD34789ED31F Q35169028-3E2B17B1-DFE0-422D-A255-B4C1D4DB9F4D Q35635652-65BB3C8E-CB0D-4020-9E65-753C393FEBC0 Q35640430-F4545F53-379E-4395-B765-E9FF391D1838 Q35672089-12D4A089-3664-4738-B20D-503C69FC58E5 Q35908084-7729A6D5-FEAA-4FD6-A967-060C667EA738 Q35941284-8A0A792E-5800-425D-A518-86D138516269 Q36310839-CB1479F3-2BB9-41E2-A9C1-656B07F28368 Q36329228-CD12F7C1-E92B-478F-B901-A9D634462562 Q36482785-5CD36ECC-448F-4CA1-B5E5-8D5B952C19CD Q36684146-A38E9B84-E686-45FA-8EC5-C8ADCD3A71F4 Q36785827-21DC1E8B-70A2-48F7-8983-A243F8CB619A Q37441394-51E8A339-9153-4E4D-81B1-9151487A9DB3 Q37568933-949F8A48-71A6-4E16-987F-B283E416A4AB Q37568944-9A13C435-CE68-409F-A47E-F68305726B81 Q38626980-E67A6815-C2C4-451F-AF91-2038E71D7429 Q40306198-F2358AC7-D780-4965-939D-9BC8655E200F Q40666822-B7A187A3-C654-450C-B3D1-B949608BD7C3 Q41879559-5E3C8FA9-8659-47E4-9462-F67CBB1727BE Q42529536-B2F8A037-8C98-4B68-8DAA-C88F3E659F4D Q42583041-235A003D-A61E-4F08-A548-D004B9B9EAF9 Q43215544-93E054A9-DB1B-430F-AC2E-986703E88204 Q50044377-A675D8DB-1A3D-4DA1-B43E-495D2C1910A8 Q51932254-6C7A40C9-06D0-476A-B301-FC4A86457441

P2860

Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

http://www.wikidata.org/entity/Q35134599

description

1997 nî lūn-bûn

@nan

1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Pharmacokinetic-pharmacodynami ...... ous and intermittent infusion.

@ast

Pharmacokinetic-pharmacodynami ...... ous and intermittent infusion.

@en

type

label

Pharmacokinetic-pharmacodynami ...... ous and intermittent infusion.

@ast

Pharmacokinetic-pharmacodynami ...... ous and intermittent infusion.

@en

prefLabel

Pharmacokinetic-pharmacodynami ...... ous and intermittent infusion.

@ast

Pharmacokinetic-pharmacodynami ...... ous and intermittent infusion.

@en

P1433

Q35134599-BC22E3B1-3655-40EB-A656-1079AD6A5990

P1476

Q35134599-4373DA32-B6EC-44D6-A1F3-74E798751BD0

P2093

Q35134599-176D848B-A5C9-4B3C-9E87-BDD04326D3A1

Q35134599-7CBE59DB-8114-4910-8BEC-4E75BBF2DDDA

Q35134599-BB6F1A67-6C88-4551-8918-76BCA3D4D6B4

P2860

Q35134599-0263F7BF-761B-48D0-9424-DE6D64F6EB82

Q35134599-5D6105C1-F040-4D5E-B317-FE0C8E8AF516

Q35134599-9CA8C448-EE13-4410-A97C-66FF505E34EF

Q35134599-A19EB4AF-B553-4007-AD76-AE4039C444BE

Q35134599-ABDD3A39-65FE-4FC2-B009-F42A17570566

Q35134599-AEB74396-AC40-4279-A38D-494B40D146A8

Q35134599-D861CE4E-E282-4554-B9D2-067E8E3F2A3C

P304

Q35134599-968C2782-0676-4AA0-83CF-CACA16E42EBC

P31

Q35134599-6CEB1452-A24C-4C59-8DDF-23104A41F3B7

P356

Q35134599-707C322D-AC4C-4A4A-8543-042FAEFF90CE

P407

Q35134599-C1292430-F1FB-4988-B1CB-215C470F8437

P433

Q35134599-3AF9EE4F-BE83-4631-97E1-C814AC6F8FE8

P478

Q35134599-91FD9931-2236-4E86-9475-287411757C62

P577

Q35134599-2B967EBF-3B1C-489A-98C1-7EFC45DDDE19

P698

Q35134599-44935A48-255A-42AC-B565-D5BDF0C93ADA

P932

Q35134599-CDE07316-4B9C-4AF0-A006-BA6E1D9FA1E3

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetic-pharmacodynami ...... uous and intermittent infusion

@en

P2093

Mouton JW

http://www.w3.org/2001/XMLSchema#string

Punt NC

http://www.w3.org/2001/XMLSchema#string

Vinks AA

http://www.w3.org/2001/XMLSchema#string

P2860

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.

Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa.

Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.

A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.

In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

P304

733-738

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.41.4.733

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

1997-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9087479

http://www.w3.org/2001/XMLSchema#string

P932

163784

http://www.w3.org/2001/XMLSchema#string